OBJECTIVE To explore the expression of the MDR1/P-glycoprotein, Fas and survivin and to examine their correlation with the biologic behavior of bladder transitional cell carcinoma (BTCC).
METHODS Immunohistochemistry was used to examine the expression of P-gp, survivin and Fas in BTCC (n=64) and normal bladder mucosa (n=12).
RESULTS The expression level of P-gp and survivin in BTCC was higher compared to normal bladder mucosa (P<0.01) and their expression was strongly correlated with clinical grading (P<0.01). In BTCC and normal bladder mucosa Fas expression was 50% and 100%, respectively (P<0.01). Recurrent BTCC showed higher expression than primary BTCC (P<0.01) and the expression of P-gp in BTCC had a reverse correlation with Fas expression but no correlation with survivin expression.
CONCLUSUON The MDR of BTCC was strongly correlated with the expression of P-gp and Fas, but was not correlated with survivin expression. Thus, enhancing cancer sensitivity to chemotherapy by reversing multidrug resistance with reversal agents or up-regulating Fas expression by apoptotic enhancing agents, might be a potential therapy to prevent tumor recurrence and invasiveness.
McKnight JJ, Gray SB, O’Kane HF, et al. Apoptosis and chemotherapy for bladder cancer. J Urol. 2005;173:683–690.PubMedCrossRefGoogle Scholar
Friedrich K, Wieder T, Von Haefen C, et al. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene. 2001;20:2749–2760.PubMedCrossRefGoogle Scholar
Radetzki S, Kohne CH, von Haefen C, et al. The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines. Oncogene. 2002;21:227–238.PubMedCrossRefGoogle Scholar
Hasegawa S, Abe T, Naito S, et al. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer. 1995;71:907–913.PubMedGoogle Scholar
Nakagawa M, Emoto A, Nasu N, et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol. 1997;157:1260–1265.PubMedCrossRefGoogle Scholar
Cao L, Duchrow M, Windhovel U, et al. Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur J Cancer. 1998;34:1612–1617.PubMedCrossRefGoogle Scholar
Tada Y, Wada M, Migita T, et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer. 2002;98:630–635.PubMedCrossRefGoogle Scholar
Yuan JL, Wang H, Wang PF, et al. Expression of P-glycoprotein in transitional cell carcinoma of urinary bladder and its significe in recurrence. Journal of Third Military Medical University (Chinese). 2000;22:1176–1178.Google Scholar
Yakirevich E, Sabo E, Naroditsky I, et al. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol. 2006;100:152–159.PubMedCrossRefGoogle Scholar
Sagol O, Yavuzsen T, Oztop I, et al. The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreastic carcinoma. Pancreas. 2005;30:343–348.PubMedCrossRefGoogle Scholar
Yin F, Shi YQ, Zhao B, et al. Suppression of P-gp induced multiple resistance in a drug resistant gastric cancer cell line by overexpression of Fas. World J Gastroenterol. 2000;6:664–670.PubMedGoogle Scholar